Redhill biopharma ltd. (RDHL)
Income statement / Quarterly
Jun'18Jun'17
NET REVENUES

2,350

483

COST OF REVENUES

725

272

GROSS PROFIT

1,625

211

RESEARCH AND DEVELOPMENT EXPENSES, net

6,044

8,434

SELLING, MARKETING AND BUSINESS DEVELOPMENT EXPENSES

3,123

3,376

GENERAL AND ADMINISTRATIVE EXPENSES

2,015

1,940

OPERATING LOSS

-9,557

-13,539

FINANCIAL INCOME

156

2,523

FINANCIAL EXPENSES

1,717

7

FINANCIAL INCOME (EXPENSES), net

-1,561

2,516

LOSS AND COMPREHENSIVE LOSS FOR THE PERIOD

-11,118

-11,023

LOSS PER ORDINARY SHARE (U.S. dollars):
Basic and diluted

0.05

0.06

WEIGHTED AVERAGE OF ORDINARY SHARES (in thousands)

213,439

171,640